PDC 2019

2019
Asia Pneumococcal & Meningococcal Disease Conference
30–31 March Manila, Philippines
Pfizer, Inc.
18/F - 20/F 8 Rockwell Building,
Hidalgo Drive, Rockwell Center, Poblacion, Makati City
March 2019
xx-xxx-xxx-xxxx

2019
Asia Pneumococcal & Meningococcal Disease Conference
30–31 March Manila, Philippines
Current Options, Rational Decisions

Disclosure
This conference is sponsored by Pfizer Vaccines and most speakers or their institutions have received an honorarium for their time and input into the content
of their abstracts and presentations.
Disclaimer
The content contained in this meeting abstract book represents the opinions and experiences of the respective presenters only and does not necessarily
represent the views or recommendations of Pfizer. For specific information regarding therapeutic agents, including Pfizer products, please refer to the
approved prescribing information in your country.

2019
Asia Pneumococcal & Meningococcal Disease Conference
30–31 March Manila, Philippines
WELCOME MESSAGE
Dear Doctor,
Welcome to Manila for the annual Asia Pneumococcal and Meningococcal Disease Conference (PDC)
to be held on 30–31 March 2019. The PDC provides a platform for scientific exchange and sharing of
experience for experts throughout the region.
The theme this year is Current Options, Rational Decisions. The first day’s sessions are
on pneumococcal and meningococcal disease in pediatrics, and on day two on adult pneumococcal
disease.
The esteemed international and regional faculty will provide updates on epidemiology and burden
of pneumococcal and meningococcal disease globally and in Asia, and discuss currently available
options for, and their impact on, disease prevention. This, together with the latest on international
recommendations and local vaccination policies, will inform decision-making processes for patients
throughout Asia.
The sessions will feature live voting questions, and there will be ample opportunity for discussion and
interaction with the faculty and your peers from around the region.
Thank you once again for taking the time out of your schedules to attend the PDC, and we hope that
you enjoy your time in the vibrant city of Manila.
Yours sincerely,
Adriano Arguedas Mohs, MD
Vaccines Scientific Affairs Medical Lead for Asia
Pfizer Inc.
Amgad Gamil, MD, MBA
Emerging Markets, Regional Medical Lead Africa,
Middle East (AfME) & Asia Regions, Vaccines
Pfizer Inc.
1

AGENDA – Day 1 • PDC
Saturday, 30 March 2019
Time Topic Speaker/Chairperson
08:00–08:15 Welcome remarks and meeting objectives Amgad Gamil
Session 1: Pneumococcal Disease in Pediatrics: Global Perspectives
08:15–08:55 PCVs eighteen years after introduction in children: Did we live up to
our expectations?
08:55–09:35 Changes in pneumococcal serotype distribution following the
introduction of pneumococcal vaccination
09:35–10:15 Nasopharyngeal colonization with Streptococcus pneumoniae:
Mechanics of surveillance and lessons learned
Jaime Santos
Ron Dagan
Eun Hwa Choi
Stephen Pelton
10:15–10:40 Coffee Break
10:40–11:10 Pneumococcal nasopharyngeal ecology and herd effect of
pneumococcal conjugate vaccines
11:10–11:40 Why is pneumococcal conjugated vaccine so different from other
vaccines?
Stephen Pelton
Ron Dagan
11:40–12:20 Panel discussion All speakers of Session 1
12:20–13:15 Lunch
Session 2: Pneumococcal Disease in Pediatrics: Regional Perspectives
13:15–13:35 Current epidemiology and serotype distribution of pneumococcal
infections in Taiwan five years after a successful implementation of
PCV13 in the National Immunization Program
13:35–13:55 Epidemiology of pediatric community-acquired pneumonia in
Japan following the introduction of PCV7 and PCV13 in the National
Immunization Program in Japan
13:55–14:15 Improving PCV13 access in the Philippines through the Expanded
Program on Immunization
14:15–14:35 Community-acquired pneumonia in children in India: How PCV13
introduction in the National Immunization Program can benefit Indian
children
Ron Dagan
Chun-Yi Lu
Naruhiko Ishiwada
Anna Ong-Lim
Srinivas G. Kasi
14:35–15:15 Panel discussion All speakers of Session 2
15:15–15:35 Coffee Break
Session 3: Meningococcal Disease Among Risk Groups
Stephen Pelton
15:35–16:05 Epidemiology and risk of meningococcal disease: Global perspective Marco Aurélio Sáfadi
16:05–16:35 Scientific evidence and global recommendation for vaccination of
children against meningococcus
16:35–16:55 Mass gatherings: Expanding vaccination strategies beyond
meningococcal vaccination
Federico Martinón-Torres
Helmy Haja Mydin
16:55–17:25 Panel discussion All speakers of Session 3
17:25–17:30 Closing of Day 1 Amgad Gamil
2

AGENDA – Day 2 • PDC
Sunday, 31 March 2019
Time Topic Speaker/Chairperson
08:30–08:45 Recap of Day 1 and introduction to Day 2 Adriano Arguedas Mohs
08:45–08:55 Objectives of Day 2 Amgad Gamil
Session 4: Pneumococcal Disease and Current Recommendations among
Adults
Helen Oh and
Julio Ramirez
08:55–09:25 Global pneumococcal disease burden in adults Charles Feldman
09:25–09:55 Pneumococcal upper respiratory tract colonization in adults: Latest
update
09:55–10:25 Evaluation of real-world effectiveness of pneumococcal vaccination
among adults
Krzysztof Trzciński
Julio Ramirez
10:25–10:45 Q&A
10:45–11:00 Break
11:00–11:30 International recommendations for adult pneumococcal vaccination Charles Feldman
11:30–11:45 Vaccination policy on adult pneumococcal diseases in Hong Kong Margaret Ip
11:45–12:00 Adult pneumococcal disease in Singapore: Vaccination policy Helen Oh
12:00–12:15 Adult pneumococcal disease in Taiwan: Vaccination Policy Kuang-Yao Yang
12:15–12:55 Panel discussion All speakers of Session 4
12:55–13:00 Closing remarks Amgad Gamil
13:00 Lunch
Product indications and prescribing information may differ in each country. Please use products in accordance with the approved indication(s) and
prescribing information in your country.
3

FACULTY BIOGRAPHIES
Adriano Arguedas MohsPfizer
Adriano Arguedas Mohs is a Costa Rican citizen who was born in Brazil and is a Pediatric Infectious
Diseases Specialist. Dr Arguedas Mohs completed his residency in Pediatrics at the University of
Costa Rica (1988) and a Fellowship in Pediatric Infectious Diseases at the University of California,
Irvine (1991).
Currently resides in Collegeville, PA, USA and is the Scientific Affairs Lead for Emerging Markets in
Asia at Pfizer Inc.; he is also a Senior Lecturer in the Faculty of Medicine, Universidad de Ciéncias
Médicas in San José, Costa Rica. He has been a clinical instructor at the University of California, Irvine
and the University of Costa Rica and member of the Ethics Committee and of the Pharmacotherapy
Committee of the National Children’s Hospital of Costa Rica.
From 1992–2000 he served in various positions in the National Children’s Hospital of Costa Rica:
1991–1993: Attending Physician at the Department of Infectious Diseases; 1993–1998 Clinical Chief at
Medicine 1 Service; 1998–2000 Chief of the Emergency and Outpatient Department and Member of
the Hospital Technical Council. From 2001–2003 he was Head of the Division of Pediatric Research at
Neeman - ICIC and from 2003 to 2012 Founder and Director of the Instituto de Atención Pediátrica.
Dr Arguedas Mohs has a total of 120 publications in peer-reviewed journals, contributed in 15 chapters
for various medical textbooks, presented 150 papers at scientific conferences and given 250 lectures
at scientific meetings. He belongs to several global scientific committees and his current research
area focuses on disease prevention by new vaccines. He was awarded the Merle Carson Lectures
(Los Angeles, California, 1991) for the best research presentation in Southern California and twice
the prize awarded for scientific work (second place) for the Latin American Society of Pediatric
Infectious Disease Clinic (San José, Costa Rica [2007] and Guayaquil-Ecuador [2009]).
Eun Hwa Choi Korea
Eun Hwa Choi, MD, PhD, is a Professor of Pediatric Infectious Diseases in the Department of Pediatrics
at Seoul National University College of Medicine in Seoul, Korea.
Dr Choi earned her medical degree from Seoul National University in 1990. She completed a residency
in pediatrics and a clinical fellowship in pediatric infectious diseases at Seoul National University
Hospital. She then completed a 4-year research fellowship at the Immunocompromised Host Section
of the National Institutes of Health’s National Cancer Institute in Bethesda, Maryland, from 1999-2003.
In 2013, she conducted research on pneumococcal vaccine at the Division of Infectious Diseases of
Children’s Hospital Boston, Massachusetts.
Dr Choi’s research interests are focused on respiratory infections, particularly on the respiratory
virus and mycoplasma in children. Her research has been published in a number of peer-reviewed
journals, including Clinical Infectious Diseases, Journal of Infectious Diseases and Journal of Clinical
Microbiology.
Dr Choi currently serves the Korean Centers for Disease Control as a member of the Expert
Committee of Immunization Practice. She is also a chair of the Korean Pediatric Society’s Committee
on Infectious Disease.
4

FACULTY BIOGRAPHIES
Ron Dagan Israel
Ron Dagan is Distinguished Professor of Pediatrics and Infectious Diseases at the Ben-Gurion
University of the Negev, Beer-Sheva. He founded the Pediatric Infectious Disease Unit at the
Department of Pediatrics, Soroka University Medical Center, Beer-Sheva, Israel, and served as its
director from 1987 to June 2014. His previous appointments include Adjunct Associate Professor of
Pediatrics at the University of Rochester, New York, USA, from 1993 to 1998, in addition to Advisor for
Infectious Diseases at the Israeli Ministry of Health. Professor Dagan obtained his MD degree in 1974
from the Hadassah Medical School of the Hebrew University, Jerusalem, Israel. In 1982, he embarked
on a 3-year Fellowship in pediatric infectious diseases at the University of Rochester, Rochester, NY.
A member of several national and international advisory committees and medical and scientific
associations, Professor Dagan was the Chairman of the Advisory Committee for Infectious Diseases
of the Israeli Society of Pediatrics from 1992 to 1997 and has served on the National Advisory
Committee on Infectious Diseases and Immunization since 1991. He is also a Founding Member of
the World Society of Pediatric Infectious Diseases (WSPID) and a Fellow of the Infectious Diseases
Society of America (IDSA). He served as a member of the Executive Committee of the International
Society of Infectious Disease (ISID) from 2010 to 2016. Professor Dagan has been involved in the
World Health Organization (WHO) Working Group on Pneumococcal Nasopharyngeal Carriage and
the WHO Pneumonia Radiology Working Group. He served as President of the European Society
for Paediatric Infectious Diseases (ESPID) from 2004 to 2006, as President of the World Society for
Pediatric Infectious Diseases (WSPID) from 2006 through 2009 and as Chair of the Board of the
International Symposia on Pneumococcus and Pneumococcal Diseases (ISPPD) from 2010 to mid-
2016.
Professor Dagan serves on the editorial board of several peer-reviewed journals, including Pediatric
Infectious Disease Journal, Infection, Human Vaccines, Journal of Infectious Diseases, Vaccine and
International Journal of Infectious Diseases. He is a recipient of many grants and awards. During his
professional career, he has contributed over 500 original articles, reviews and book chapters, and
has presented more than 500 papers at national and international scientific meetings. Professor
Dagan has earned international recognition for his research, which has focused largely on the
development on vaccine preventable diseases, with particular emphasis on pneumococcal vaccines;
the understanding of hepatitis A epidemiology and introduction of hepatitis A vaccines; the
epidemiology of respiratory infections in children; clinical aspects of vaccination against antibioticresistant
pneumococci; the pathology of otitis media, role of resistant organisms in otitis media and
prediction of bacteriological response to various antibiotics; and the epidemiology and prevention
of enteric and invasive infections in young children.
5

FACULTY BIOGRAPHIES
6

FACULTY BIOGRAPHIES
7

FACULTY BIOGRAPHIES
8

FACULTY BIOGRAPHIES
9

FACULTY BIOGRAPHIES
10

FACULTY BIOGRAPHIES
11

FACULTY BIOGRAPHIES
12

FACULTY BIOGRAPHIES
13

ABSTRACTS: SESSION 1
14

ABSTRACTS: SESSION 1
15

ABSTRACTS: SESSION 1 & 2
16

ABSTRACTS: SESSION 2
17

ABSTRACTS: SESSION 2 & 3
18

ABSTRACTS: SESSION 3
19

ABSTRACTS: SESSION 4
20

ABSTRACTS: SESSION 4
21

ABSTRACTS: SESSION 4
22

ABSTRACTS: SESSION 4
23

Philippines Prevenar 13® Abbreviated Prescribing Information
Pneumococcal Conjugate Vaccine, 13-Valent
Prevenar 13® Suspension for Intramuscular (IM) Injection Pre-filled syringe
APPROVED INDICATIONS
Active immunization for the prevention of invasive
disease, pneumonia and acute otitis media caused by
Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B,
7F, 9V, 14, 18C, 19A, 19F and 23F in infants, children and
adolescents.
Decreased appetite, irritability, drowsiness/increased
sleep, restless sleep/decreased sleep, diarrhea, vomiting,
rash, fever, any vaccination-site erythema, induration/
swelling or pain/tenderness, vaccination-site erythema or
induration/swelling 2.5 cm – 7.0 cm (after toddler dose
and in older children [age 2 to 5 years])
For adults aged 18 years and older, Pneumococcal
Conjugate Vaccine, 13-Valent (adsorbed) (Prevenar 13)
is indicated for the prevention of pneumococcal disease
(including pneumonia and invasive disease) caused by
Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F,
9V, 14, 18C, 19A, 19F and 23F.
DOSAGE AND METHOD OF ADMINISTRATION
Pneumococcal Conjugate Vaccine, 13-Valent
(adsorbed) (Prevenar 13) schedule for Infants and
Toddlers:
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed) (Prevenar 13)
Routine Vaccination Schedule for Infants and Toddlers
Dose Dose 1*† Dose 2† Dose 3† Dose 4‡
Age at Dose 2 months 4 months 6 months 12-15 months
* Dose 1 may be given as early as 6 weeks of age.
† The recommended dosing interval is 4 - 8 weeks.
‡ The fourth dose should be administered at approximately 12-15 months of age, and at
least 2 months after the third dose.
Pneumococcal Conjugate Vaccine, 13-Valent
(adsorbed) (Prevenar 13) schedule for children 24
months to 17 years of age:
Children 24 months to 5 years of age and children 6
years to 17 years of age may receive a single dose of
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed)
(Prevenar 13) whether or not they have been previously
vaccinated with 1 or more dose of Pneumococcal 7-valent
conjugate vaccine. If pneumococcal 7-valent conjugate
vaccine was previously administered, then at least 8
weeks should elapse before receiving Pneumococcal
Conjugate Vaccine, 13-Valent (adsorbed) (Prevenar 13).
Adults aged 18 years and older:
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed)
(Prevenar 13) is to be administered as a single dose
to adults 18 years and older including those previously
vaccinated with a pneumococcal polysaccharide vaccine.
CONTRAINDICATIONS
Hypersensitivity to any component of the vaccine,
including diphtheria toxoid.
PRECAUTIONS
Safety and immunogenicity data on Pneumococcal
Conjugate Vaccine, 13-Valent (adsorbed) (Prevenar
13) are not available for individuals in specific
immunocompromised groups (e.g., malignancy, or
nephrotic syndrome) and vaccination should be
considered on an individual basis.
UNDESIRABLE EFFECTS
Infants and children aged 6 weeks to 5 years
Children and adolescents aged 5 to 17 years
Decreased appetite, irritability, drowsiness/increased
sleep, restless sleep/decreased sleep, headaches,
diarrhea, vomiting, rash, urticaria or urticaria-like rash,
fever, any vaccination-site erythema, induration/swelling
or pain/tenderness, vaccination-site tenderness (including
impaired movement)
Adults aged 18 years and older
Decreased appetite, headaches, diarrhea, vomiting, rash,
generalized new/aggravated joint pain; generalized new/
aggravated muscle pain, chills, fatigue, vaccinationsite
erythema, vaccination-site induration/swelling,
vaccination-site pain/tenderness, limitation of arm
movement, fever
DRUG INTERACTION
Different injectable vaccines should always be given at
different vaccination-sites.
Infants and children aged 6 weeks to 5 years
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed)
(Prevenar 13) can be given with any of the following
vaccine antigens, either as monovalent or combination
vaccines: diphtheria, tetanus, acellular or whole-cell
pertussis, Haemophilus influenzae type b, inactivated
poliomyelitis, hepatitis A, hepatitis B, meningococcal
serogroup C, measles, mumps, rubella, varicella, and
rotavirus.
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed)
(Prevenar 13) can also be given concomitantly between
12-23 months of age with the tetanus toxoid conjugated
meningococcal polysaccharide serogroups A, C, W and Y
vaccine.
Children and adolescents 6 to 17 years of age
In children and adolescents, there are no data on the
concomitant administration of Pneumococcal Conjugate
Vaccine, 13-Valent (adsorbed) (Prevenar 13) with human
papillomavirus vaccine (HPV), meningococcal protein
conjugate vaccine (MCV4), or tetanus, diphtheria and
accellar pertussis vaccine (Tdap).
Adults 18 to 49 years of age
No data are currently available regarding concomitant use
with other vaccines.
Adults 50 years and older
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed)
(Prevenar 13) can be administered concomitantly with
trivalent or quadrivalent inactivated influenza vaccine
(TIV or QIV)
For full product information see product leaflet.
ALPD Ver. No.: 9.0
Reference: LPD Revision No.: 9.0 dated 29 November 2017
24

Philippines Nimenrix Abbreviated Prescribing Information
Meningococcal polysaccharide serogroups A, C, W-135 and
Y conjugate vaccine
Nimenrix 5 mcg Lyophilized Powder for Solution for Injection (IM)v
THERAPEUTIC INDICATION/S.
Nimenrix is indicated for active immunisation of
individuals from the age of 6 weeks against invasive
meningococcal diseases caused by Neisseria
meningitidis serogroup A, C, W-135 and Y.
DOSAGE AND METHOD OF ADMINISTRATION.
This product should be used in accordance with
available meningococcal vaccine recommendations.
Infants from 6 to 12 weeks of age:
The recommended immunisation series consists of three
doses, each of 0.5 ml. The primary infant series consists
of two doses, with the first dose given from 6 weeks of
age and with an interval of 2 months between doses. The
third (booster) dose is recommended at 12 months of age.
Children from 12 months of age, adolescents and adults:
A single 0.5 ml dose should be administered.
A second dose of Nimenrix may be considered appropriate
for some individuals.
Previously vaccinated children from 12 months of age,
adolescents and adults:
Nimenrix may be given as a booster dose in individuals
who have previously received primary vaccination with
a conjugated or plain polysaccharide meningococcal
vaccine.
Method of administration
Immunisation should be carried out by intramuscular
injection only.
In infants, the recommended injection site is the
anterolateral aspect of the thigh. In individuals from 1 year
of age, the recommended injection site is the anterolateral
aspect of the thigh or the deltoid muscle.
CONTRAINDICATIONS.
Hypersensitivity to the active substances of this
vaccine or to any of the following excipients: Sucrose,
Trometamol, and Sodium chloride.
SPECIAL WARNINGS AND PRECAUTIONS FOR
USE.
Meningococcal polysaccharide serogroups A, C, W-135
and Y conjugate vaccine (Nimenrix) should under
no circumstances be administered intravascularly,
intradermally or subcutaneously.
Vaccination with this product should be postponed in
subjects suffering from an acute severe febrile illness. The
presence of a minor infection, such as a cold, should not
result in the deferral of vaccination.
Syncope (fainting) can occur following, or even before,
any vaccination especially in adolescents as a psychogenic
response to the needle injection.
This vaccine should be given with caution to individuals
with thrombocytopenia or any coagulation disorder
since bleeding may occur following an intramuscular
administration to these subjects.
Nimenrix will only confer protection against Neisseria
meningitidis serogroup A, C, W-135 and Y. The vaccine
will not protect against any other Neisseria meningitidis
serogroups.
Nimenrix does not substitute for tetanus immunisation.
Giving Nimenrix with or one month before a TT-containing
vaccine in the second year of life does not impair the
response to TT or significantly affect safety. No data are
available beyond the age of 2 years.
DRUG INTERACTIONS.
In infants, Nimenrix can be given concomitantly with
combined DTaP-HBV-IPV/Hib vaccines and with 10-valent
pneumococcal conjugate vaccine.
From age 1 year and above, Nimenrix can be given
concomitantly with any of the following vaccines: hepatitis
A (HAV) and hepatitis B (HBV) vaccines, measles - mumps -
rubella (MMR) vaccine, measles - mumps - rubella - varicella
(MMRV) vaccine, 10-valent pneumococcal conjugate
vaccine or unadjuvanted seasonal influenza vaccine.
In the second year of life, Nimenrix can also be given
concomitantly with combined diphtheria - tetanus -
acellular pertussis (DTaP) vaccines, including combination
DTaP vaccines with hepatitis B, inactivated poliovirus or
Haemophilus influenzae type b (HBV, IPV or Hib) such as
DTaP-HBV-IPV/Hib vaccine, and 13-valent pneumococcal
conjugate vaccine.
Whenever possible, Nimenrix and a TT containing vaccine,
such as DTaP-HBV-IPV/Hib vaccine, should be coadministered
or Nimenrix should be administered at least
one month before the TT containing vaccine.
If Meningococcal polysaccharide serogroups A, C, W-135 and
Y conjugate vaccine (Nimenrix) is to be co-administered,
the vaccines should always be administered at different
injection site.
It may be expected that in patients receiving
immunosuppressive treatment an adequate response may
not be elicited.
UNDESIRABLE EFFECTS.
Pain, redness, swelling, irritability, drowsiness, loss
of appetite, fever, headache, fatigue, gastrointestinal
symptoms and fever.
For full product information see product leaflet.
ALPD Ver. no: 2.0
Reference: LPD Rev 2.0 dated 28 Nov 2017
For Healthcare Professionals Only. Full Prescribing Information is available upon request.
Product indications and prescribing information may differ in each country.
Please use products in accordance with the approved indication(s) and prescribing information in your country.
25